News
Zacks.com on MSN2d
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study GoalVertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.
We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...
StockStory.org on MSN2d
Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower TodayWhat Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the ...
Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.
Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings ...
StockStory.org on MSN3d
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion ...
In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...
Aug 5 - Vertex Pharmaceuticals (NASDAQ:VRTX) shares dropped nearly 17% on Tuesday after its experimental pain medication, ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback